.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Baxter
AstraZeneca
Cipla
McKesson
Express Scripts
Merck
Colorcon
Daiichi Sankyo
McKinsey

Generated: December 14, 2017

DrugPatentWatch Database Preview

M.V.I.-12 Drug Profile

« Back to Dashboard

Which patents cover M.v.i.-12, and when can generic versions of M.v.i.-12 launch?

M.v.i.-12 is a drug marketed by Hospira and Teligent Pharma Inc and is included in two NDAs.

The generic ingredient in M.V.I.-12 is ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine; riboflavin 5'-phosphate sodium; thiamine; vitamin a; vitamin e. There are six drug master file entries for this compound. Additional details are available on the ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine; riboflavin 5'-phosphate sodium; thiamine; vitamin a; vitamin e profile page.

Summary for M.V.I.-12

You have an error in your SQL syntax; check the manual that corresponds to your MariaDB server version for the right syntax to use near 'SODIUM','THIAMINE HYDROCHLORIDE','VITAMIN A','VITAMIN E') AND hsdb_drugname IS N' at line 1
US Patents:0
Applicants:2
NDAs:2
Suppliers / Packagers: 1
Bulk Api Vendors: 80
Patent Applications: 8,080